Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Both Measure Up 1 (n=847) and 2 (n=836) met their co-primary endpoints, showing more patients randomised to treatment with upadacitinib (oral JAK inhibitor; 15mg or 30mg) than placebo achieved an EASI-75 and vIGA-AD response (score of 0 [clear] or 1 [almost clear]) at week 16.

SPS commentary:

At least a 75% improvement in EASI score from baseline (EASI-75 response) was achieved at week 16 in 70% of the upadacitinib 15mg group, 80% of the upadacitinib 30mg group and 16% of the placebo group in Measure Up 1, and by 60%, 73% and 13%, respectively, in Measure Up 2.

A vIGA-AD response (validated Investigator's Global Assessment for Atopic Dermatitis score of 0 [clear] or 1 [almost clear] with ≥2 grades of reduction from baseline) was achieved at week 16 in 48% of the upadacitinib 15mg group, 62% of the 30mg group and 8% of placebo in Measure Up 1, and in 39%, 52% and 5%, respectively, in the Measure Up 2 study.

 

The results of the AD Up Phase III study of upadacitinib versus placebo, used in addition topical corticosteroids, in adolescents with moderate to severe atopic dermatitis have been published separately.

Source:

The Lancet

Resource links:

Comment

AD Up study